Barry L. Shulkin

Guidelines for Imaging and Staging of Neuroblastic Tumors: Consensus Report from the International Neuroblastoma Risk Group Project

Hervé J. Brisse, M. Beth McCarville, Claudio Granata et al. · Radiology · 2011 · 522 citations

Medicine, Oncology, Radiology +15

Pheochromocytomas: Imaging with 2-[Fluorine-18]fluoro-2-deoxy-<scp>d</scp>-glucose PET

Barry L. Shulkin, Norman W. Thompson, Brahm Shapiro et al. · Radiology · 1999 · 304 citations

Medicine, Nuclear Medicine, Oncology +17

Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial

Rajen Mody, Arlene Naranjo, Collin Van Ryn et al. · The Lancet Oncology · 2017 · 273 citations · Full text

Medicine, Oncology, Pharmacotherapy +9

Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032

Alice L. Yu, Andrew L. Gilman, M. Fevzi Özkaynak et al. · Clinical Cancer Research · 2021 · 216 citations · Full text

Life Sciences, Immunology, Oncology +17

Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children’s Oncology Group

Gregory A. Yanik, Marguerite T. Parisi, Barry L. Shulkin et al. · Journal of Nuclear Medicine · 2013 · 210 citations · Full text

Medicine, Nuclear Medicine, Oncology +16